Table 1.

Demographic and medication data

	Percentage or mean (SD); range
Gender	56% men
Age (years)	66.6 (9.9); 46–89
Education (years)	16.9 (2.2); 12–21
Duration of PD diagnosis (years)	6.9 (5.0); 1–23
Modified Hoehn and Yahr stage 1	25.0%
Modified Hoehn and Yahr stage 1.5	0.0%
Modified Hoehn and Yahr stage 2	40.6%
Modified Hoehn and Yahr stage 2.5	28.1%
Modified Hoehn and Yahr stage 3	6.3%
History of clinical fluctuationsa,b	46.4%
History of dyskinesiasa,b	28.6%
History of fallsb,c	19.4%
Sleep disturbancesa	50.0%
L-dopa equivalents (mg/day)d	546.2 (404.3); 0–2101
Medication type (%)
L-dopa	91
Dopamine agonist	69
MOA-B-inhibitor (Selegiline)	31
COMT-inhibitor (Entacapone)	22
Amantadine	19
Anticholinergic (Trihexyphenidyl)	9
CoQ10	9
Psychotropic/other	6

Notes: SD = standard deviation; L-dopa medications include levodopa–carbidopa, levodopa–carbidopa–entacapone, carbidopa, levodopa; dopamine agonist medications include pramipexole, ropinirole, pergolide; Psychotropic/other medications included Paroxetine for depression and Neurontin for pain. Those on Stalevo were considered to be on both L-dopa and a COMT-inhibitor.

^aFour to five participants' scores were unavailable for these questions.

^bScores were dichotomized (feature present or not present).

^cOne participant's score was unavailable.

^dL-dopa equivalents = regular levodopa dose × 1 + levodopa continuous release (CR) dose × 0.75 + pramipexole dose × 67 + ropinirole dose × 16.67 + pergolide dose × 100 + bromocriptine dose × 10 + [regular levodopa dose + (continuous release levodopa dose × 0.75)] × 0.25 if taking tolcapone (Hobson et al., 2002); one participant's L-dopa equivalent could not be calculated because of missing dosages.